FDA advisors voted 19-0, with one abstention, that the immediate-release oxycodone formulation RoxyBond should be approved to treat chronic pain, and the majority agreed that it could carry abuse-deterrent labeling for both the intranasal and intravenous routes of abuse.
Trending:
FDA Panel Backs Abuse-Deterrent Immediate-Release Opioid